Search

Arvinas Inc

Geschlossen

BrancheGesundheitswesen

8.27 -0.36

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

8.18

Max

8.28

Schlüsselkennzahlen

By Trading Economics

Einkommen

227M

169M

Verkäufe

234M

250M

KGV

Branchendurchschnitt

32.308

56.432

EPS

2.58

Gewinnspanne

67.841

Angestellte

246

EBITDA

216M

159M

Empfehlungen

By TipRanks

Empfehlungen

Buy

12-Monats-Prognose

+80.51% upside

Dividenden

By Acuity

Nächstes Ergebnis

4. Nov. 2026

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

29M

549M

Vorheriger Eröffnungskurs

8.63

Vorheriger Schlusskurs

8.27

Nachrichtenstimmung

By Acuity

50%

50%

115 / 339 Ranking in Healthcare

Arvinas Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

17. Sept. 2026, 19:36 UTC

Arvinas Inc is higher today, advancing since Wednesday's close, despite earlier pulling back from a session high but remaining above its opening level.

16. Sept. 2026, 19:03 UTC

Arvinas Inc shares fell sharply, continuing a downward trend and remaining below the 20-day moving average, with no recovery from an early dip.

15. Sept. 2026, 20:02 UTC

Arvinas Inc shares are trading lower, marking six consecutive daily declines. The stock remains below its 20-day moving average amid negative market sentiment.

11. Sept. 2026, 20:08 UTC

Arvinas Inc. shares are lower today, remaining below their 20-day moving average amid broader market inflation concerns following recent Consumer Price Index data.

10. Sept. 2026, 20:07 UTC

Arvinas Inc shares are lower today, marking four consecutive sessions of declines amid broader market trends and rising Treasury yields.

2. Sept. 2026, 19:46 UTC

Arvinas Inc shares are higher during Wednesday's session, showing unusual strength despite a slight pullback from earlier highs. No specific news was identified.

28. Aug. 2026, 20:08 UTC

Arvinas Inc. shares are lower as U.S. Treasury yields rise amid inflation concerns. Trading remains routine, with shares finishing below earlier highs.

27. Aug. 2026, 19:36 UTC

Arvinas Inc. shares are higher during Thursday's session, trading within a narrow range and above the 20-day moving average.

26. Aug. 2026, 20:08 UTC

Arvinas Inc shares are lower today as the pharmaceuticals sub-sector declines amid broader market weakness since Tuesday's close. No specific news was identified.

25. Aug. 2026, 23:01 UTC

Arvinas Inc shares are higher in after-market trading amid a broader positive sentiment following a decrease in crude oil prices and U.S. sanctions on Iran.

24. Aug. 2026, 19:56 UTC

Arvinas Inc. shares are lower today amid broader market pressures, including a significant drop in crude oil prices linked to U.S.-Iran relations.

21. Aug. 2026, 19:56 UTC

Arvinas Inc is trading higher, reflecting broader market gains despite no specific company news. The stock remains above its 20-day moving average.

20. Aug. 2026, 20:01 UTC

Arvinas Inc shares are lower today, reflecting broader market pressures amid concerns over consumer spending following Walmart Inc's disappointing earnings report.

19. Aug. 2026, 19:26 UTC

News

Arvinas Inc shares are higher, buoyed by positive analyst ratings. BTIG maintains a "buy" with an $18 target, while Barclays raises its target to $20.

17. Aug. 2026, 19:16 UTC

Arvinas Inc shares are higher during Monday's session, reflecting positive market performance. The stock has gained since Friday's close, despite a decline in retail sales.

14. Aug. 2026, 19:46 UTC

Arvinas Inc shares are lower amid significant downward pressure in the Pharmaceuticals sub-sector. The stock remains above its 20-day moving average.

13. Aug. 2026, 19:46 UTC

Arvinas Inc. shares are higher today, maintaining a position above their 20-day moving average and near the upper end of their one-month range.

11. Aug. 2026, 19:26 UTC

Arvinas Inc. shares are trading lower as the Pharmaceuticals sub-sector declines, despite a peak shortly after the market opened. No specific news was identified.

10. Aug. 2026, 19:56 UTC

News

Analysts updated ratings on Arvinas Inc, with Citigroup lowering its target to $21 and Evercore ISI reducing its target to $14. Shares are trading higher.

7. Aug. 2026, 19:51 UTC

Arvinas Inc is rising amid a broader market rally, with no specific company news driving the move. The stock remains above its 20-day moving average.

6. Aug. 2026, 19:46 UTC

News

Arvinas Inc reported earnings per share of $2.58, exceeding estimates. Revenue reached $249.7 million, driving shares higher in Thursday's session.

5. Aug. 2026, 20:03 UTC

News

Arvinas shares are lower following Wells Fargo's downgrade to Equal-Weight and a price target cut to $11, despite Wedbush raising its target to $12.

4. Aug. 2026, 20:02 UTC

Social Media
News

Arvinas Inc shares rose following strong Q2 results, with EPS of $2.58 and revenue of $249.7 million, surpassing analyst expectations. BTIG reiterated its Buy rating.

3. Aug. 2026, 19:46 UTC

News

Arvinas Inc. shares are lower today, continuing a downward trend since Friday. Barclays raised its price target from $18.00 to $20.00 while maintaining an "overweight" rating.

31. Juli 2026, 20:06 UTC

Arvinas Inc shares are declining amid broader market trends and rising Treasury yields. The stock remains below its 20-day moving average.

29. Juli 2026, 16:36 UTC

Arvinas shares are lower today, trading near the lower end of their one-month range amid rising oil prices and inflation concerns.

28. Juli 2026, 20:06 UTC

Arvinas Inc's shares are lower today, reflecting broader market trends amid a significant decline in Asian indices, particularly the Nikkei 225.

24. Juli 2026, 19:26 UTC

Arvinas Inc. shares are lower amid a broader market decline influenced by falling crude oil prices, now near the lower end of their one-month range.

22. Juli 2026, 20:06 UTC

Arvinas Inc. shares are near unchanged amid routine trading and cautious market sentiment ahead of the Federal Reserve meeting.

21. Juli 2026, 20:06 UTC

Arvinas Inc shares are higher during Tuesday's session, tracking gains in the Nasdaq 100 Index amid strong technology sector performance. No specific news was identified.

Peer-Vergleich

Kursveränderung

Arvinas Inc Prognose

Kursziel

By TipRanks

80.51% Vorteil

12-Monats-Prognose

Durchschnitt 14.964 USD  80.51%

Hoch 21 USD

Tief 8.68 USD

Basierend auf 11 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Arvinas Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

11 ratings

5

Buy

6

Halten

0

Sell

Stimmung

By Acuity

115 / 339 Ranking in Gesundheitswesen

Nachrichtenstimmung

Neutral

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Unterdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Arvinas Inc

Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer, which are in Phase 1/2 clinical trials; and ARV-471, an orally bioavailable estrogen receptor degrading PROTAC targeted protein degrader for the treatment of patients with locally advanced or metastatic estrogen receptor+/human epidermal growth factor receptor 2-breast cancer, which is Phase 3 clinical trial. Arvinas, Inc. has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut.